Skip to main content
Quest Diagnostics
Connect with an expert
Call
Menu

Evaluate the source of cognitive symptoms with blood biomarker testing

When paired with clinical cognitive testing, our AD-Detect® ABeta 42/40 and p-tau217 Evaluation can help uncover a broader view of what may be contributing to your patient's cognitive impairment. And the sooner you have that information, the sooner you and your patients can take actions like

  • Make more informed referrals so that specialists are ready to take the best next step in patient care
  • Take a proactive approach to planning for the future and care team support 
  • Integrate lifestyle improvements to mitigate risk and help delay disease progression
Learn how primary care plays a leading role

Take an integrated approach to cognitive health

As a primary care provider, you understand the comprehensive health of your patients. The Quest AD-Detect portfolio can expand that view, helping you know when to intervene—and when to refer. 

Identify patients with cognitive symptoms or memory changes

Integrate the AD-Detect® ABeta 42/40 and p-tau217 Evaluation with clinical cognitive testing as part of understanding the source of symptoms

Take the appropriate next steps, which could be monitoring changes or referring to a specialist 

Identifying patients who may benefit

 The following indicators, aside from family history, help determine who might benefit from assessment2:

  

Blood testing can help uncover microstructural changes in the brain3

Once cognitive impairment is significant enough to be observed through clinical assessment tools such as mini-mental state examinations (MMSE) or other cognitive questionnaires, AD biomarkers may have already been increasing.

Expand your approach to assessment with our AD-Detect® portfolio

Integrating blood biomarker testing into assessment of cognitive symptoms means additional information for you to deliver more—more biomarkers, more insights, and ultimately a more positive patient experience overall. Combining clinical cognitive assessments and insights from blood biomarker testing allows you to balance clinical evaluations with objective data.  

Test code

Test name

Test use

14258

AD-Detect® ABeta 42/40 and p-tau217 Evaluation

Combines two biomarker levels into one interpretation to establish the likelihood of AD

11786

Quest AD-Detect® Beta-Amyloid 42/40 Ratio, Plasma

Detect Aβ levels, one of the earliest biomarkers associated with AD risk.9 Levels can be monitored over time.

13690

Quest AD-Detect® Phosphorylated tau181 (p-tau181), Plasma

Uncover the presence of p-tau181 proteins, one of the key biomarkers involved in the diagnosis and staging of AD.7 Levels can be monitored over time.

13825

Quest AD-Detect® Phosphorylated tau217 (p-tau217), Plasma

Determine levels of p-tau217 proteins, a dynamic and specific biomarker to aid in differentiating AD from other neurocognitive diseases.

12563

Quest AD-Detect® Apolipoprotein E (ApoE)

Determine hereditary AD risk, excluding early-onset AD. Additionally useful in determining risk of amyloid-related imaging abnormalities (ARIA) associated with disease modifying therapies.9

  

Empowering patients to act

Understanding if their symptoms are related to Alzheimer's disease earlier allows patients to take action and make decisions for the future, such as

    • Building a care team 

    • Making financial preparations 

    • Legal planning 

    • Navigating lifestyle changes, additional testing, clinical trials, or treatment

The results are in podcast: Integrating blood biomarkers for Alzheimer’s risk assessment

Dr Michael Racke discusses the role of blood biomarkers in early Alzheimer’s risk assessment and the impact on patient care through proactive diagnosis.

Learn more

A revolution in Alzheimer’s disease healthcare is underway

A report from Quest Diagnostics reveals physician and US adult perspectives on the current and future landscape of dementia and Alzheimer’s disease evaluation, testing, treatment, and care.  

95%

of physicians agree that the value of a blood test for the early risk of Alzheimer’s disease depends on the quality of education around it.4

91%

of physicians say a blood test for the early assessment of Alzheimer’s disease risk will revolutionize how physicians diagnose the disease.4

81%

of physicians say a blood test for the early assessment of risk will revolutionize how Alzheimer’s disease is monitored over time.4

 

Continue the conversation

Start including the Quest AD-Detect® portfolio in your preventive testing today. We are here, ready to answer questions. Connect with one of our in-house experts to continue the conversation, or see the full cognitive testing portfolio here.

 

744

* indicates required
References
  1. Schindler SE, Galasko D, Pereira, AC et al. Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer’s disease. Nat Rev Neurol. Published online June 12, 2024. doi:10.1038/s41582-024-00977-5
  2. Yu J-T, Xu W, Tan C-C, et al. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91(11):1201-1209. doi:10.1136/jnnp-2019-321913
  3. DeSimone JC, Wang WE, Loewenstein DA, et al. Diffusion MRI relates to plasma a?42/40 in PET negative participants without dementia. Alzheimers Dement. 2024;20(4):2830-2842. doi:10.1002/alz.13693
  4. Vermunt L, Sikkes SAM, van den Hout A, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888-898. doi:10.1016/j.jalz.2019.04.001
  5. Quest Diagnostics. The Coming Alzheimer’s Disease Healthcare Revolution US Physician and Adult Perspectives on the Future of Diagnostics and Treatment. May 2022. Accessed July 1, 2024. https://www.questdiagnostics.com/content/dam/corporate/brochure-pdfs/The-Coming-Alzheimer%27s-Disease-Healthcare-Revolution-Survey-Report.PDF
  6. Lantero Rodriguez J, Karikari TK, Suárez-Calvet M, et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to postmortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140(3):267-278. doi:10.1007/s00401-020-02195-x
  7. Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021;17(8):1353-1364. doi:10.1002/alz.12301 
  8. Weber DM, Taylor SW, Lagier RJ, et al. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment. Front Neurol. 2024;15:1364658. doi:10.3389/fneur.2024.1364658

Our company

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.